

### Posidyne® NEO Intravenous Filter Set



# Neonatal air-eliminating filter set for 96-hour bacterial and endotoxin retention

- ▶ **0.2 µm Posidyne Membrane** Provides documented 96-hour bacterial and inadvertant bacteria-associated endotoxin retention for patient protection
- ▶ Slim, low-profile housing design Provides low hold-up volume
- ▶ Surfactant-free hydrophilic Posidyne membrane Permits easy priming
- ▶ Small, round housing Easy to secure and comfortable for the patient
- ▶ Guideline compliance Meets INS,¹ NAVAN,² ASPEN,³ and FDA⁴ guidelines

#### **Product Description**

The Posidyne NEO Intravenous Filter Set features the  $0.2~\mu m$  Posidyne NEO air-eliminating filter. The ultra low filter volume enables rapid delivery of bolus medication and minimum fluid hold-up. The  $0.2~\mu m$  Posidyne membrane offers patient protection against particles, microbes, associated endotoxin, and entrained air.

#### **Specifications**

#### Usage

Single patient use; 96-hour maximum use

#### Filter Media

0.2 um hydrophilic Posidyne membrane provides phthalate-free fluid pathway.

#### Sterility

Sterile and non-pyrogenic

#### **Maximum Working Pressure**

30 psi

#### **Priming Volume**

0.4 mL

#### **Hold-Up Volume**

 $< 0.2 \, \text{mL}$ 

#### Indications for Use

Inadvertent contamination of intravenous infusions can have serious consequences:

- Particulate Contamination Arises from a variety of sources, intrinsically in infusate and equipment, and extrinsically due to manipulations. Studies have demonstrated that particles may cause phlebitis on peripheral infusion lines and may have serious systemic effects,<sup>5</sup> damaging the lung by irritation of endothelium and by deposition in microvasculature.<sup>6</sup>
- Entrained Air Results from degassing of solutions, incomplete priming, or with disconnection. Entrained air is especially problematic on central lines, leading to air emboli.<sup>7</sup>
- Microbial Contamination IV administration systems may become contaminated inadvertently due to manipulations.<sup>8</sup>
  Some bacteria can grow rapidly in infusion fluids, increasing the infection risk.<sup>9,10</sup>
- Associated Endotoxin Endotoxin has serious effects on the inflammatory, cardiovascular, pulmonary, and coagulation systems.<sup>11</sup> It is released by Gram-negative bacteria and has been shown to be able to penetrate conventional IV filters.<sup>12</sup> Only filters that retain associated endotoxin can be safely used for more than 24 hours.<sup>13</sup>

## PALL Medical

#### Pall Medical 25 Harbor Park Dr Port Washington, NY 11050

516.484.3600 phone medical.pall.com web uscustomerservice@pall.com email

#### Europe

Pall Medical a division of Pall Europe Ltd Europa House, Havant Street Portsmouth PO1 3PD, England

+44 (0)23 9230 3452 phone +44 (0)23 9230 3324 fax Biosvc@Pall.com E-mail

#### **Ordering Information** (U.S. and Europe)

<i>USA</i> Part Number	Description	Pkg
NEO96	Posidyne NEO Intravenous Filter Set with ultra-microbore tubing & luer lock adapters	40/case
NEO96NY	Posidyne NEO Intravenous Filter Set with ultra-microbore tubing, needleless 'Y' site, & luer lock adapters	40/case
<i>Europe</i> Part Number	Description	Pkg
NEO96E	Posidyne NEO Intravenous Filter Set with ultra-microbore tubing, luer lock adapters, 70 mm downstream extension, & side clamp	50/case
NEO96LE	Posidyne NEO Intravenous Filter Set with ultra-microbore tubing, luer lock adapters, 250 mm downstream extension, & side clamp	50/case
NEO96NYE	Posidyne NEO Intravenous Filter Set with ultra- microbore tubing, needleless access Y-site, 100 mm downstream extension, & side clamp	50/case

#### References

- 1. Intravenous Nursing Society Standards of Practice. J.B. Lippincott, 1997.
- National Advisory Group on Standards and Practice Guidelines for Parenteral Nutrition. JPEN J Parenter Enteral Nutr. 1998; 22:49-66.
- Mirtallo J, Canada T, Johnson D, Kumpf V, Petersen C, Sacks G, Seres D, Guenter P, Task Force for the Revision of Safe Practices for Parenteral Nutrition. Parenteral nutrition administration. In: Safe practices for parenteral nutrition. JPEN J Parenter Enteral Nutr. 2004 Nov-Dec; 28(6):S65-70.
- Food & Drug Administration lock adapters. FDA safety alert: Hazards of precipitation associated with parenteral nutrition. Rockville, MD, USA: Dept of HHS, *Public Health Services*, April 18, 1994.
- Falchuk KH, Peterson L, McNeil BJ. N Engl J Med. Jan 10, 1985; 312:78-82.
- 6. Kirkpatrick CJ. Krankenhauspharmazie. 1988; 9:487-90.
- 7. Coppa GF, Gouge TH, Hofstetter SR. *JPEN J Parenter Enteral Nutr.* 1981; 5:166-8.
- 8. Groves MJ. *Parenteral Technology Manual*, 2nd ed., Interpharm Press, 1989.
- 9. Holmes CJ, Kundsin RB, Ausman RK, Walter CW. J Clin Microbiol. 1980; 12:725-31.
- 10. Bozzetti F, Bonfanti G, Regalia E. Nutr Clin Pract. 1990; 5:156-9.
- 11. Rietschel ET, Brade H. Sci Am. 1992; 1:52-6.
- 12. van Lingen A, et al. J Clin Microbiol Infect. 1997; 3:122.
- 13. Richards C, Grassby PF. J Clin Pharm Ther. 1994; 19:199-202.

#### Visit us on the Web at www.pall.com

#### Email us at HospitalInsideSales@pall.com

#### International Offices

Pall Corporation has offices and plants throughout the world in locations such as: Argentina, Australia, Austra, Belgium, Brazil, Canada, China, France, Germany, Hong Kong, India, Indonesia, Ireland, Italy, Japan, Korea, Malaysia, Mexico, the Netherlands, New Zealand, Norway, Poland, Puerto Rico, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, the United Kingdom, the United States, and Venezuela. Distributors in all major industrial areas of the world.

The information provided in this literature was reviewed for accuracy at the time of publication. Product data may be subject to change without notice. For current information consult your local Pall distributor or contact Pall directly.

© 2009, Pall Corporation. Pall, (ALL), and Posidyne are trademarks of Pall Corporation. ® indicates a registered trademark in the USA. Filtration. Separation. Solution.su is a service mark of Pall Corporation.